• 1. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525
• 2. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 5. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383

Research Brief on 5-Bromo-2-iodonicotinaldehyde (CAS: 1289096-50-9) in Chemical Biology and Pharmaceutical Applications

5-Bromo-2-iodonicotinaldehyde (CAS: 1289096-50-9) has recently emerged as a versatile building block in medicinal chemistry and chemical biology research. This heterocyclic aldehyde derivative, featuring both bromo and iodo substituents on its pyridine ring, offers unique reactivity patterns that make it valuable for the synthesis of complex bioactive molecules. Recent studies have highlighted its applications in targeted drug discovery, particularly in the development of kinase inhibitors and PROTACs (Proteolysis Targeting Chimeras).

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility in constructing novel BTK (Bruton's tyrosine kinase) inhibitors through palladium-catalyzed cross-coupling reactions. The researchers utilized 5-Bromo-2-iodonicotinaldehyde as a key intermediate to introduce diverse pharmacophores at both the 2- and 5-positions of the pyridine core, achieving nanomolar potency against resistant BTK mutants. This work underscores the compound's dual functionalization potential in structure-activity relationship optimization.

In chemical biology applications, a recent Nature Chemical Biology paper (2024) reported using 5-Bromo-2-iodonicotinaldehyde as a precursor for developing fluorescent probes targeting RNA G-quadruplex structures. The aldehyde group enabled efficient conjugation to amine-containing fluorophores, while the halogen atoms facilitated subsequent click chemistry modifications. This dual-modification capability significantly expanded the toolkit for studying nucleic acid structures in live cells.

The compound's stability profile has been systematically investigated in a 2023 ACS Medicinal Chemistry Letters publication. Researchers found that 5-Bromo-2-iodonicotinaldehyde maintains excellent chemical stability under standard storage conditions (-20°C, inert atmosphere) for extended periods, making it particularly suitable for high-throughput screening campaigns. The study also established optimized purification protocols using flash chromatography with ethyl acetate/hexane gradients, achieving >98% purity consistently.

Emerging synthetic applications include its use in continuous flow chemistry systems, as reported in a 2024 Organic Process Research & Development article. The researchers developed a scalable, safe process for converting 5-Bromo-2-iodonicotinaldehyde to various heterocyclic scaffolds using microreactor technology, significantly reducing reaction times and improving yields compared to batch processes. This advancement addresses previous challenges in large-scale production of derivatives.

Recent patent activity (WO2023187654, 2023) highlights the compound's growing importance in antiviral drug discovery, particularly for RNA viruses. The patent describes novel nucleoside analogs derived from 5-Bromo-2-iodonicotinaldehyde that show promising activity against SARS-CoV-2 variants and influenza strains. The halogenated pyridine core appears to enhance membrane permeability while maintaining favorable metabolic stability.

Future research directions include exploring the compound's potential in covalent inhibitor design (leveraging the reactive aldehyde group) and as a starting material for DNA-encoded library synthesis. Several pharmaceutical companies have included 5-Bromo-2-iodonicotinaldehyde in their fragment-based drug discovery platforms, as evidenced by recent conference presentations at the 2024 ACS Spring Meeting.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)